In vitro release of tegafur from a fatty-base suppository and in vivo bioavailability of tegafur.
This study was designed to determine the in vitro release of tegafur from a suppository and the in vivo bioavailability of tegafur in rats. Two different suppository preparations (product A-1 and product A-2) containing 750 mg of tegafur were tested for in vitro release of tegafur by the Muranishi Method (membrane diffusion method) and the partially modified paddle method (permeability through dialysis tubing). When determined by either method, the amount of tegafur released from product A-2 during the whole experimental period was significantly greater than that released from product A-1. When tested by the Muranishi method, however, the difference in the amount released during the first 10-min period was not significant. A greater bioavailability of tegafur after rectal administration was obtained by product A-2 more than product A-1. A significant correlation was observed between the in vitro release and the in vivo bioavailability. The present results indicate that there are considerable differences in physiochemical characteristics between product A-1 and product A-2.
D000818:Animals; D001682:Biological Availability; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008297:Male; D010539:Permeability; D051381:Rats; D011919:Rats, Inbred Strains; D013488:Suppositories; D005641:Tegafur / Q000008:administration & dosage*
D013488:Suppositories; D005641:Tegafur